Quanterix Expands Laboratory Developed Test Menu with Launch of Neurofilament Light Chain Test
Retrieved on:
Monday, January 9, 2023
Health, Neurology, Other Science, Research, Science, Biotechnology, Simoa, Multiple sclerosis, RUO, Blood, Neurodegeneration, CSF, CLIA, Ageing, RRMS, SLAC National Accelerator Laboratory, MS, Laboratory developed test, AFL, HIV, Amyotrophic lateral sclerosis, Corporation, Microangiopathy, LDT, FDA, Risk, Neurology, Plasma, TBI, ISO 15189, Protein, Diagnosis, Central nervous system, CAR, Therapy, Patient, HIV/AIDS, Research, ISO, Stroke, Serum, Nerve, Concussion, Traumatic brain injury, Clinical trial, Cerebrospinal fluid, ALS, Medical device, Pharmaceutical industry, Medical imaging, Parkinsonism
NfL is a well-studied biomarker for neuro-axonal injury with wide applicability to different neurological disorders.
Key Points:
- NfL is a well-studied biomarker for neuro-axonal injury with wide applicability to different neurological disorders.
- Any disorder or injuring force resulting in neuronal damage can lead to the release of NfL into the interstitial fluid and cerebrospinal fluid (CSF).
- A fraction of these proteins diffuses into the blood, where concentrations are typically 50- to 100-fold lower than in CSF and difficult to measure with conventional immunoassay technologies.
- “Assessment and monitoring of brain health is incredibly difficult and typically performed in limited fashion by surgery or imaging.